Skip to content
TrialScanner

NCT03601455

Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer

Phase 2Active, not recruitingAZNCollaborator

Registry record

Lead sponsor
Jonsson Comprehensive Cancer Center
Conditions
Bladder Urothelial Carcinoma; Stage IV Bladder Cancer AJCC v8; Stage IVA Bladder Cancer AJCC v8; Stage IVB Bladder Cancer AJCC v8
Primary completion
Jan 31, 2027Sponsor estimate
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Sponsor estimate: the sponsor registered this date in advance and can move it. A primary completion date is when the last participant is measured, not when results are announced.

Open NCT03601455 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT03601455: Radiation Therapy and... | TrialScanner